New blood test could replace risky amniocentesis for genetic disorders
NCT ID NCT03743948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new blood test that looks for fetal cells in the mother's blood to diagnose genetic diseases in the baby. It aimed to replace invasive tests like amniocentesis, which carry a small risk of miscarriage. The trial enrolled 18 pregnant women but was terminated early, so we don't yet know if the test works well enough.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could offer a safer, non-invasive way to diagnose genetic disorders in unborn babies, reducing the need for risky procedures like amniocentesis.
- What could go wrong
- The trial was terminated early with only 18 participants, so results are limited. The test may fail due to low fetal cell counts or technical issues, and it is not yet proven reliable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOGENIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
INSERM-Hospital,
Montpellier, Herault, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.